Micro Imaging Technology, Inc. Enters Phase 1 Of Its Collaboration With Northern Michigan University

SAN CLEMENTE, CA--(Marketwired - March 18, 2014) - Micro Imaging Technology, Inc. (OTCQB: MMTC) announced today that it has delivered an MIT 1000 System as part of its collaboration with Northern Michigan University (NMU) to identify and differentiate Staphylococcus aureus (S. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA). As the Company previously announced, the goal of the collaboration is to rapidly and cost-effectively identify these two particular healthcare threats using the MIT 1000 System, a bacterial cell based identification system that can identify pathogenic bacteria in three minutes (average) at significant cost savings per test.

The MIT 1000 System now resides in the laboratory of Dr. Josh Sharp, NMU professor of Microbiology. “We are glad to finally have the MIT 1000,” Dr. Sharp said. “The collaboration between us and MIT can now proceed in earnest. This project has important implications in healthcare and also provides a unique educational opportunity for students at NMU. The aim of the collaboration project between my lab and MIT is not only to develop this technology to detect S. aureus and MRSA, but down the road, other human pathogens as well. We can now gain experience in using the System which will also aid in writing collaborative proposals for grants offered by National Institutes of Health, US Department of Agriculture, and other sources.”

Dr. David Haavig, MIT Chief Scientist, said, “We are excited that Dr. Sharp and his students can now utilize the MIT 1000 in their research, using the System in a wide variety of bacterial testing situations. They will also employ the System to investigate new clinical applications for the MIT 1000 such as the MRSA issue. The potential benefits of this joint research project may spread far beyond our initial goals and we are grateful to Dr. Sharp and NMU for their participation.”

About: Northern Michigan University

Northern Michigan University, located in Marquette, Michigan, is a dynamic four-year, public, coeducational university that has grown its reputation based on its award-winning leadership programs, cutting-edge technology initiatives and nationally recognized academic programs. The university’s fastest growing academic areas are clinical science, biology, and the geographical and environmental sciences. Northern Michigan has a population of about 9,000 undergraduate and graduate students. It offers 180 degree programs, including 18 graduate programs.

About: Micro Imaging Technology, Inc.

Micro Imaging Technology, Inc. is a California-based public company that is also registered to do business under the name Micro Identification Technologies. MIT has developed and patented the MIT 1000, a stand-alone, rapid, optically-based, software driven system that can identify pathogenic bacteria and complete an identification test, after culturing, in three (3) minutes (average) at the lowest cost per test when compared to any other conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process requires only clean filtered water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3.5 billion, which is expected to surpass $4.7 billion by 2015 according to BCC Research. In addition, the recently passed “New” U.S. Food Safety Bill is expected to further accelerate the current annual growth rate of 6.6 percent.

In June 2009, the AOAC Research Institute (AOAC RI) awarded the Company Performance Tested Methods SM (PTM) certification for the rapid identification of Listeria. The AOAC RI provides an independent third party evaluation and expert reviews of methods and will award PTM certification to methods that demonstrate performance levels equivalent or better than other certified bacteria identifying methods. The MIT System underwent hundreds of individual tests, including ruggedness and accuracy, to earn AOAC RI’s certification for the identification of Listeria.

You can find more information about our company and about Micro Identification Technologies™. Please visit our newly enhanced website at www.micro-identification.com.

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission, reference MMTC: www.sec.gov.